Dong Keon Yon, MD, PhD

Articles by Dong Keon Yon, MD, PhD

Q&A: Addressing the Hidden Burden of MASLD in Clinical Practice

ByJiyeon Oh, MD,Min Seo Kim, MD, MS,Dong Keon Yon, MD, PhD,Luke Halpern, Associate Editor

May 10th 2026

Metabolic dysfunction-associated steatotic liver disease (MASLD) remains largely underdiagnosed and asymptomatic, creating major opportunities for pharmacists to drive early identification, lifestyle intervention, and metabolic risk management.

Q&A: Why Obesity and Diabetes Are Driving the MASLD Epidemic

ByJiyeon Oh, MD,Min Seo Kim, MD, MS,Dong Keon Yon, MD, PhD,Luke Halpern, Associate Editor

April 29th 2026

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects 1.3 billion people globally, driven by metabolic disease trends, highlighting urgent needs for earlier detection, prevention, and pharmacist-led intervention.